Published in Rheumatology (Oxford) on July 23, 2015
Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol (2015) 1.02
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2016) 0.89
Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford) (2016) 0.86
New discovery rarely runs smooth: an update on progranulin/TNFR interactions. Protein Cell (2015) 0.84
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol (2016) 0.84
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83
Targeting Imbalance between IL-1β and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse Corneas. Am J Pathol (2016) 0.79
Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol (2016) 0.79
Genetic Variation in Toll-Interacting Protein Is Associated With Leprosy Susceptibility and Cutaneous Expression of Interleukin 1 Receptor Antagonist. J Infect Dis (2015) 0.78
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A (2016) 0.78
The inflammasome as a target for pain therapy. Br J Anaesth (2016) 0.76
Co-morbidity of PTSD and immune system dysfunction: opportunities for treatment. Curr Opin Pharmacol (2016) 0.75
Distinct role of IL-1β in instigating disease in Sharpin(cpdm) mice. Sci Rep (2016) 0.75
Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances. F1000Res (2016) 0.75
Microbiota and caspase-1/caspase-8 regulate IL-1β-mediated bone disease. Gut Microbes (2016) 0.75
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci U S A (2017) 0.75
Phytomedicine in Joint Disorders. Nutrients (2017) 0.75
IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases. Front Pharmacol (2017) 0.75
Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. Front Immunol (2017) 0.75
[Caspase-1 regulates autoinflammation in rheumatic diseases]. Z Rheumatol (2016) 0.75
A Brief History of IL-1 and IL-1 Ra in Rheumatology. Front Pharmacol (2017) 0.75
Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology (2017) 0.75
Biologic basis for interleukin-1 in disease. Blood (1996) 16.04
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 11.62
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
Type 2 diabetes as an inflammatory disease. Nat Rev Immunol (2011) 8.30
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest (2002) 5.52
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med (2005) 4.79
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev (2008) 4.14
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum (2007) 3.65
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med (2009) 3.56
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Anti-inflammatory Agents: Present and Future. Cell (2010) 3.13
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab (2010) 3.11
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun (2001) 2.94
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 2.77
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A (2006) 2.59
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care (2009) 2.56
An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet (2014) 2.40
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood (2014) 2.30
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis (2009) 2.29
IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol (2011) 2.25
Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum (2009) 2.23
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum (2005) 2.13
The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) (2002) 2.10
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2008) 2.08
Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A (2010) 2.04
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2009) 2.03
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum (2010) 2.00
Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A (2001) 1.97
Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol (2009) 1.82
Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med (2014) 1.80
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79
The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol (2009) 1.78
Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum (2010) 1.75
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis (2013) 1.72
Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation (2012) 1.70
Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.69
TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol (2000) 1.68
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 1.64
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol (2004) 1.57
Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol (2005) 1.55
Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum (2009) 1.54
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart (2009) 1.53
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum (2010) 1.52
Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care (2012) 1.46
Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α. Proc Natl Acad Sci U S A (2011) 1.41
Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) (2010) 1.38
IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol (2007) 1.38
Inflammasome and IL-1beta-mediated disorders. Curr Allergy Asthma Rep (2010) 1.37
Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant (2008) 1.37
Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis (2006) 1.34
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A (2009) 1.31
Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med (2004) 1.29
Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis (2007) 1.27
Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2011) 1.27
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis (2014) 1.26
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis (2011) 1.26
Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum (2011) 1.25
Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. J Allergy Clin Immunol (2007) 1.23
Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep (2011) 1.20
Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail (2010) 1.19
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care (2013) 1.18
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev (2014) 1.16
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum (2012) 1.16
A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol (2008) 1.15
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine (2009) 1.15
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis (2011) 1.15
Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol (1993) 1.13
Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum (2008) 1.13
Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant (2011) 1.13
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther (2011) 1.12
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) (2003) 1.10
Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum (2012) 1.10
Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One (2012) 1.08
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr (2010) 1.07
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood (2010) 1.06
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol (2013) 1.05
Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol (2014) 1.04
On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis (2011) 1.04